Mink therapeutics to participate at btig biotechnology conference

New york, aug. 02, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced that the company will attend the btig 2022 biotechnology conference. mink will participate virtually and host one-on-one meetings with investors on august 8th and 9th.
INKT Ratings Summary
INKT Quant Ranking